Connor Thunshelle1,2, Michael R Hamblin2,3,4. 1. 1 Harvard College , Cambridge, Massachusetts. 2. 2 Wellman Center for Photomedicine , Massachusetts General Hospital, Boston, Massachusetts. 3. 3 Department of Dermatology, Harvard Medical School , Boston, Massachusetts. 4. 4 Harvard-MIT Division of Health Sciences and Technology , Cambridge, Massachusetts.
Abstract
BACKGROUND: Low-level laser therapy (LLLT) or photobiomodulation (PBM) is a possible treatment for brain injury, including traumatic brain injury (TBI). METHODS: We review the fundamental mechanisms at the cellular and molecular level and the effects on the brain are discussed. There are several contributing processes that have been proposed to lead to the beneficial effects of PBM in treating TBI such as stimulation of neurogenesis, a decrease in inflammation, and neuroprotection. Both animal and clinical trials for ischemic stroke are outlined. A number of articles have shown how transcranial LLLT (tLLLT) is effective at increasing memory, learning, and the overall neurological performance in rodent models with TBI. RESULTS: Our laboratory has conducted three different studies on the effects of tLLLT on mice with TBI. The first studied pulsed against continuous laser irradiation, finding that 10 Hz pulsed was the best. The second compared four different wavelengths, discovering only 660 and 810 nm to have any effectiveness, whereas 732 and 980 nm did not. The third looked at varying regimens of daily laser treatments (1, 3, and 14 days) and found that 14 laser applications was excessive. We also review several studies of the effects of tLLLT on neuroprogenitor cells, brain-derived neurotrophic factor and synaptogenesis, immediate early response knockout mice, and tLLLT in combination therapy with metabolic inhibitors. CONCLUSIONS: Finally, some clinical studies in TBI patients are covered.
BACKGROUND: Low-level laser therapy (LLLT) or photobiomodulation (PBM) is a possible treatment for brain injury, including traumatic brain injury (TBI). METHODS: We review the fundamental mechanisms at the cellular and molecular level and the effects on the brain are discussed. There are several contributing processes that have been proposed to lead to the beneficial effects of PBM in treating TBI such as stimulation of neurogenesis, a decrease in inflammation, and neuroprotection. Both animal and clinical trials for ischemic stroke are outlined. A number of articles have shown how transcranial LLLT (tLLLT) is effective at increasing memory, learning, and the overall neurological performance in rodent models with TBI. RESULTS: Our laboratory has conducted three different studies on the effects of tLLLT on mice with TBI. The first studied pulsed against continuous laser irradiation, finding that 10 Hz pulsed was the best. The second compared four different wavelengths, discovering only 660 and 810 nm to have any effectiveness, whereas 732 and 980 nm did not. The third looked at varying regimens of daily laser treatments (1, 3, and 14 days) and found that 14 laser applications was excessive. We also review several studies of the effects of tLLLT on neuroprogenitor cells, brain-derived neurotrophic factor and synaptogenesis, immediate early response knockout mice, and tLLLT in combination therapy with metabolic inhibitors. CONCLUSIONS: Finally, some clinical studies in TBI patients are covered.
Authors: Amir Oron; Uri Oron; Jackson Streeter; Luis De Taboada; Alexander Alexandrovich; Victoria Trembovler; Esther Shohami Journal: J Neurotrauma Date: 2012-01-04 Impact factor: 5.269
Authors: Justin A Zivin; Gregory W Albers; Natan Bornstein; Thomas Chippendale; Bjorn Dahlof; Thomas Devlin; Marc Fisher; Werner Hacke; William Holt; Sanja Ilic; Scott Kasner; Robert Lew; Marshall Nash; Julio Perez; Marilyn Rymer; Peter Schellinger; Dietmar Schneider; Stefan Schwab; Roland Veltkamp; Michael Walker; Jackson Streeter Journal: Stroke Date: 2009-02-20 Impact factor: 7.914
Authors: Farzad Salehpour; Sevda Gholipour-Khalili; Fereshteh Farajdokht; Farzin Kamari; Tomasz Walski; Michael R Hamblin; Joseph O DiDuro; Paolo Cassano Journal: Rev Neurosci Date: 2020-04-28 Impact factor: 4.353
Authors: Donna R Webb; Sheba R Churchill; Georgette D Hill; Christopher A McGee; Min Shi; Angela P King-Herbert; Terry L Blankenship-Paris Journal: Comp Med Date: 2021-04-16 Impact factor: 0.982